ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学内発行雑誌
  2. The Showa University journal of medical sciences
  3. Vol.28(2016)
  4. No.4

On-Demand Inhaled Corticosteroid and Fast-Acting Beta-2 Agonist Combination Therapy Versus Regular Inhaled Corticosteroid Plus Rescue Bronchodilator in Adults with Mild Asthma: A Network Meta-Analysis

https://showa.repo.nii.ac.jp/records/535
https://showa.repo.nii.ac.jp/records/535
7024c1e2-d4fe-4709-a563-1acca07971bc
名前 / ファイル ライセンス アクション
S28_359.pdf S28_359.pdf (362.4 kB)
Item type 学内発行雑誌 / Departmental Bulletin Paper(1)
公開日 2017-12-01
タイトル
タイトル On-Demand Inhaled Corticosteroid and Fast-Acting Beta-2 Agonist Combination Therapy Versus Regular Inhaled Corticosteroid Plus Rescue Bronchodilator in Adults with Mild Asthma: A Network Meta-Analysis
言語
言語 eng
資源タイプ
資源タイプ departmental bulletin paper
著者 ANDO, Koichi

× ANDO, Koichi

ANDO, Koichi

Search repository
TANAKA, Akihiko

× TANAKA, Akihiko

TANAKA, Akihiko

Search repository
YOKOE, Takuya

× YOKOE, Takuya

YOKOE, Takuya

Search repository
OHNISHI, Tsukasa

× OHNISHI, Tsukasa

OHNISHI, Tsukasa

Search repository
INOUE, Shin

× INOUE, Shin

INOUE, Shin

Search repository
SAGARA, Hironori

× SAGARA, Hironori

SAGARA, Hironori

Search repository
書誌情報 The Showa University journal of medical sciences

巻 28, 号 4, p. 359-367, 発行日 2016-12
抄録
内容記述タイプ Abstract
内容記述 The aim of this study was to assess the non-inferiority of on-demand (OD) inhaled corticosteroid (ICS) and fast-acting beta-2 agonist (FABA) combination therapy. Although regular inhalation of low-dose ICS and OD short-acting beta-2 agonist (REG-ICS+OD-SABA) is said to be effective therapy for mild asthma, we investigated whether OD-ICS/FABA is as effective as REG-ICS+OD-SABA. A network meta-analysis of randomized controlled trials was conducted to examine non-inferiority by comparing the efficacy of NON-REG+OD-ICS/FABA with REG-ICS+OD-SABA for mild asthma. We also assessed the superiority of NON-REG+OD-ICS/FABA to OD-SABA without any regular treatment (NON-REG+OD-SABA). PubMed, the Cochrane library database, and Scopus were searched to identify relevant articles with an outcome measure of the incidence of asthma control. A network meta-analysis was performed and the summary effect size was expressed as the mean difference (MD) with 95% confidence intervals (CIs). The probability of being the best treatment for the outcome and the surface under the cumulative ranking curves were also calculated. Three randomized controlled trials of treatment for mild asthma met the criteria and were included in the study. Non-inferiority of NON-REG+OD-ICS/FABA to REG-ICS+OD-SABA (MD, -0.17; 95% CI, -0.41 to 0.07) and superiority of NON-REG+OD-ICS/FABA to NON-REG+OD-SABA (MD, -0.29; 95% CI, -0.49 to -0.08) were shown in patients with mild asthma. The respective probabilities of being the best treatment for asthma control were 91.2%, 8.8% and 0.2% for NON-REG+OD-ICS/FABA, REG-ICS+OD-SABA, and NON-REG+OD-SABA, respectively, and the surface under the cumulative ranking curves were 1.0, 0.5, and 0.1, respectively. These results suggest that NON-REG+OD-ICS/FABA is an effective alternative to REG-ICS+OD-SABA for asthma control in patients with mild asthma.
DOI
関連識別子 10.15369/sujms.28.359
出版者
出版者 Showa University Society
ISSN
収録物識別子 0915-6380
著者版フラグ
出版タイプ VoR
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 12:43:58.967784
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3